Diplon, Jeffrey .

HRN: 10-41-01  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/15/2023
CO-AMOXICLAV 457MG/5ML, 70ML SUSPENSION (BOT)
10/15/2023
10/22/2023
PO
10cc
Q8
Infected Wound
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: